<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233372</url>
  </required_header>
  <id_info>
    <org_study_id>DORAVIPEP</org_study_id>
    <nct_id>NCT04233372</nct_id>
  </id_info>
  <brief_title>Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study</brief_title>
  <acronym>DORAVIPEP</acronym>
  <official_title>Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Garcia Cinca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Josep Mallolas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo
      as post exposition prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with treatment completion at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of subjects with treatment completion at day 28. Post exposition prophylaxis non-completion is considered in cases:
If the subject dies.
Does not go to visits (loss of follow-up)
Change or suspend the treatment under study for any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the baseline characteristics associated to non-completion.</measure>
    <time_frame>28 days</time_frame>
    <description>% of non-completion patients by age, sex, sexual orientation, origin, comorbilities, previous post exposition prophylaxis treatment, previous sexual transmitted infections and use of abuse drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and description of adverse reactions(clinical and laboratory) that appear during antiretroviral therapy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of adherence to combination antiretroviral therapy, including the time until loss of adherence</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that maintain follow-up</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HIV Seroconversion</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hiv</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delstrigo</intervention_name>
    <description>Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.
1 covered tablet for day .( will be administered 28 days maximum)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects attending emergency room due to potential HIV exposition of either sex:

          -  Aged 18 years or more.

          -  Who have been exposed to non-occupational HIV and who meet the prerequisites for the
             current recommendations to begin prophylaxis post-exposition with three antiretroviral
             drugs.

          -  Who after being fully informed, give their written consent to participate in the study
             and undergo the tests and examinations required.

          -  Individuals able to do follow up correctly.

        Exclusion Criteria:

          -  Pregnant women or nursing mothers or women trying to conceive during the study period.

          -  Patients in whom it is known or suspected that the source case has a resistance to one
             of the drugs from the study treatment regimens.

          -  Treatment with drugs that are contraindicated in the study or products that are in the
             investigational phase.

          -  Allergic reactions or intolerance to the compounds of the study treatment regiments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department and HIV &amp; HCV Clinical Research Unit University Hospital Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François Raffi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Josep Mallolas, MD</last_name>
      <email>mallolas@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Alexy Iniciarte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>David Garcia Cinca</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

